ALRT ALR Technologies

ALRT announces launch of the Integrated ALRT Diabetes Solution (“Integrated Solution”)

ALRT announces launch of the Integrated ALRT Diabetes Solution (“Integrated Solution”)

The Integrated Solution will include ALRT Diabetes Solution software, blood glucose test supplies and diabetes management administered by Centers of Excellence for Diabetes Care

RICHMOND, Va., June 28, 2018 (GLOBE NEWSWIRE) -- ALR Technologies Inc. (OTCPINK:ALRT) will be offering Integrated Solution to health insurance payers to help their clinical teams deliver best practice diabetes care to insulin dependent and non-insulin dependent patients.  Integrated Solution bundles blood glucose test supplies, ALRT Diabetes Solution and patient management by Certified Diabetes Educators in regional Centers of Excellence for Diabetes Care. 

The bundle will be covered by reimbursement and is priced to be competitive with test supplies available in the market.  Purchasers will have the option to select the blood glucose test supplies from 3 different manufacturers.

Integrated Solution is a cost effective platform to manage large-scale diabetes patient population.  It will facilitate dispensing diabetes care by clinical teams based on best practice guidelines. 

Centers of Excellence for Diabetes Care will perform the following functions: monitor patient performance and blood glucose data uploads, track therapy successes after each data upload, alert clinical teams for immediate care plan adjustments for patients with high A1C based on protocols set by the clinical teams and provide clinical teams with suggested reference insulin doses as needed.

Patients will receive a cash bonus after successfully registering their blood glucose meter and will receive quarterly cash bonuses if they adhere to prescribed test plans.  Additional programs will be offered to encourage and reward patient adherence.

“We developed a comprehensive software platform that provides management tools for large-scale diabetes patient populations and diagnostic tools that providers can use to optimize drug therapy treatments.  Aligning with a cost-effective manufacturers of highly rated test equipment and oversight professionals will allow us to offer an attractively priced package for health insurance payers to contain the cost of diabetes care,” said Sidney Chan, CEO of ALR Technologies and Chairman of the Board  

As part of its strategy to bring best practice diabetes care to market, ALRT is ready to commence demonstration projects using the Integrated Solution to replicate the improved outcomes for large groups of diabetes patients demonstrated in ALRT’s clinical trials and pilot.  

About ALR Technologies Inc.

ALR Technologies is a medical device company providing an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters. The System processes and streamlines collected data to support clinicians and caregivers to improve patient outcomes and assist health plans to optimize their investments in chronic disease care. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data. More information about ALR Technologies, Inc. can be found at .

Contact:    Ken Robulak:   804-554-3500 *708                      email:  

This release contains certain "forward-looking statements" relating to ALR Technologies' business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words "estimate", "expect", "anticipate", "believe" and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the Company's quarterly filings with the Securities Exchange Commission.

EN
28/06/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALR Technologies

 PRESS RELEASE

ALR Technologies Announces Sales Guidance for Q4 2022, Q1 2023, and Co...

ALR Technologies Announces Sales Guidance for Q4 2022, Q1 2023, and Completion of the GluCurve Pet CGM Manufacturing Agreement SINGAPORE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, today announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd (“Infinovo”) for the Continuous Glucose Monitor (CGM) hardware used in the GluCurve Pet CGM. The agreement gives ALRT the exclusive global rights to distribute the CGM hardware in the animal health market. Additionally, the Compa...

 PRESS RELEASE

ALR Technologies Announces Update to Singapore Migration Merger and Gl...

ALR Technologies Announces Update to Singapore Migration Merger and GluCurve Pet CGM Commercialization SINGAPORE, Sept. 30, 2022 (GLOBE NEWSWIRE) -- ALR Technologies Inc. (“ALRT”) (OTCQB: ALRT), the diabetes management company, is pleased to announce an update with respect to its migration to Singapore. Further to its Form 8-K filed May 20, 2022, and press release issued May 20, 2022, the Registration Statement on Form F-4 filed by its affiliate, ALR Technologies SG Ltd. (“ALRT Singapore”), has been declared effective by the Securities and Exchange Commission (the “SEC”). ALRT anticipates...

 PRESS RELEASE

ALR Technologies Announces Update on the GluCurve Pet CGM Distribution...

ALR Technologies Announces Update on the GluCurve Pet CGM Distribution and Commercialization SINGAPORE, Aug. 29, 2022 (GLOBE NEWSWIRE) -- ALR Technologies SG Pte. Ltd (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, announces a distribution agreement with a global leader in animal health is now anticipated to be complete in September. The delay from the previous target of late August is not expected to affect commencement of commercialization. Furthermore, the Company has placed its first Purchase Order (“PO”) for the GluCurve Pet CGM hardware with delivery schedu...

 PRESS RELEASE

ALR Technologies Announces First Shipment of GluCurve Pet CGMs Expecte...

ALR Technologies Announces First Shipment of GluCurve Pet CGMs Expected in October and Update on the Manufacturing Agreement SINGAPORE, Aug. 01, 2022 (GLOBE NEWSWIRE) -- ALR Technologies SG Pte. Ltd (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, announces the Company has received manufacturing approval from Infinovo Medical Co., Ltd. (“Infinovo”) to place the first purchase order (“PO”) for the GluCurve Pet CGM with an expected delivery date of October 2022. Furthermore, the manufacturing and supply agreement with Infinovo was subject to certain closing conditio...

 PRESS RELEASE

ALR Technologies Completes Definitive Manufacturing Agreement with Inf...

ALR Technologies Completes Definitive Manufacturing Agreement with Infinovo Medical for the GluCurve Pet CGM Hardware SINGAPORE, June 29, 2022 (GLOBE NEWSWIRE) -- ALR Technologies SG Pte. Ltd (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, announces the completion of a definitive manufacturing agreement with Infinovo Medical Co. Ltd (“Infinovo”) to manufacture and supply the Continuous Glucose Monitor (“CGM”) hardware that will be utilized as part of the ALRT GluCurve Pet CGM (the “Manufacturing Agreement”). The Manufacturing Agreement gives ALRT the exclusive gl...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch